These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases. Mehta GU; Malekzadeh P; Shelton T; White DE; Butman JA; Yang JC; Kammula US; Goff SL; Rosenberg SA; Sherry RM J Immunother; 2018 Jun; 41(5):241-247. PubMed ID: 29672342 [TBL] [Abstract][Full Text] [Related]
4. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Hershkovitz L; Levy D; Kubi A; Hovav E; Chermoshniuk N; Shalmon B; Hardan I; Catane R; Markel G; Apter S; Ben-Nun A; Kuchuk I; Shimoni A; Nagler A; Schachter J Clin Cancer Res; 2010 May; 16(9):2646-55. PubMed ID: 20406835 [TBL] [Abstract][Full Text] [Related]
5. Minimally invasive liver resection to obtain tumor-infiltrating lymphocytes for adoptive cell therapy in patients with metastatic melanoma. Alvarez-Downing MM; Inchauste SM; Dudley ME; White DE; Wunderlich JR; Rosenberg SA; Kammula US World J Surg Oncol; 2012 Jun; 10():113. PubMed ID: 22726267 [TBL] [Abstract][Full Text] [Related]
6. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. Saberian C; Amaria RN; Najjar AM; Radvanyi LG; Haymaker CL; Forget MA; Bassett RL; Faria SC; Glitza IC; Alvarez E; Parshottam S; Prieto V; Lizée G; Wong MK; McQuade JL; Diab A; Yee C; Tawbi HA; Patel S; Shpall EJ; Davies MA; Hwu P; Bernatchez C J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021033 [TBL] [Abstract][Full Text] [Related]
7. Metastatic Lung Lesions as a Preferred Resection Site for Immunotherapy With Tumor Infiltrating Lymphocytes. Ben-Avi R; Itzhaki O; Simansky D; Zippel D; Markel G; Ben Nun A; Schachter J; Besser MJ J Immunother; 2016 Jun; 39(5):218-22. PubMed ID: 27163742 [TBL] [Abstract][Full Text] [Related]
8. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Dudley ME; Gross CA; Langhan MM; Garcia MR; Sherry RM; Yang JC; Phan GQ; Kammula US; Hughes MS; Citrin DE; Restifo NP; Wunderlich JR; Prieto PA; Hong JJ; Langan RC; Zlott DA; Morton KE; White DE; Laurencot CM; Rosenberg SA Clin Cancer Res; 2010 Dec; 16(24):6122-31. PubMed ID: 20668005 [TBL] [Abstract][Full Text] [Related]
9. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. Goedegebuure PS; Douville LM; Li H; Richmond GC; Schoof DD; Scavone M; Eberlein TJ J Clin Oncol; 1995 Aug; 13(8):1939-49. PubMed ID: 7636534 [TBL] [Abstract][Full Text] [Related]
10. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen. Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492 [TBL] [Abstract][Full Text] [Related]
11. Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2. Nguyen LT; Saibil SD; Sotov V; Le MX; Khoja L; Ghazarian D; Bonilla L; Majeed H; Hogg D; Joshua AM; Crump M; Franke N; Spreafico A; Hansen A; Al-Habeeb A; Leong W; Easson A; Reedijk M; Goldstein DP; McCready D; Yasufuku K; Waddell T; Cypel M; Pierre A; Zhang B; Boross-Harmer S; Cipollone J; Nelles M; Scheid E; Fyrsta M; Lo CS; Nie J; Yam JY; Yen PH; Gray D; Motta V; Elford AR; DeLuca S; Wang L; Effendi S; Ellenchery R; Hirano N; Ohashi PS; Butler MO Cancer Immunol Immunother; 2019 May; 68(5):773-785. PubMed ID: 30747243 [TBL] [Abstract][Full Text] [Related]
12. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Weber J; Atkins M; Hwu P; Radvanyi L; Sznol M; Yee C; Clin Cancer Res; 2011 Apr; 17(7):1664-73. PubMed ID: 21325070 [TBL] [Abstract][Full Text] [Related]
13. A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma. Poschke I; Lövgren T; Adamson L; Nyström M; Andersson E; Hansson J; Tell R; Masucci GV; Kiessling R Cancer Immunol Immunother; 2014 Oct; 63(10):1061-71. PubMed ID: 24993563 [TBL] [Abstract][Full Text] [Related]
14. Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. Goff SL; Smith FO; Klapper JA; Sherry R; Wunderlich JR; Steinberg SM; White D; Rosenberg SA; Dudley ME; Yang JC J Immunother; 2010 Oct; 33(8):840-7. PubMed ID: 20842052 [TBL] [Abstract][Full Text] [Related]
15. Characterization of tumor-infiltrating lymphocytes derived from human tumors for use as adoptive immunotherapy of cancer. Schiltz PM; Beutel LD; Nayak SK; Dillman RO J Immunother; 1997 Sep; 20(5):377-86. PubMed ID: 9336745 [TBL] [Abstract][Full Text] [Related]
16. Manipulating the tumor microenvironment ex vivo for enhanced expansion of tumor-infiltrating lymphocytes for adoptive cell therapy. Chacon JA; Sarnaik AA; Chen JQ; Creasy C; Kale C; Robinson J; Weber J; Hwu P; Pilon-Thomas S; Radvanyi L Clin Cancer Res; 2015 Feb; 21(3):611-21. PubMed ID: 25472998 [TBL] [Abstract][Full Text] [Related]
18. Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care? Svane IM; Verdegaal EM Cancer Immunol Immunother; 2014 Oct; 63(10):1081-91. PubMed ID: 25099366 [TBL] [Abstract][Full Text] [Related]
19. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Besser MJ; Shapira-Frommer R; Itzhaki O; Treves AJ; Zippel DB; Levy D; Kubi A; Shoshani N; Zikich D; Ohayon Y; Ohayon D; Shalmon B; Markel G; Yerushalmi R; Apter S; Ben-Nun A; Ben-Ami E; Shimoni A; Nagler A; Schachter J Clin Cancer Res; 2013 Sep; 19(17):4792-800. PubMed ID: 23690483 [TBL] [Abstract][Full Text] [Related]
20. Adjuvant immunotherapy with tumor infiltrating lymphocytes and interleukin-2 in patients with resected stage III and IV melanoma. Ridolfi L; Ridolfi R; Riccobon A; De Paola F; Petrini M; Stefanelli M; Flamini E; Ravaioli A; Verdecchia GM; Trevisan G; Amadori D J Immunother; 2003; 26(2):156-62. PubMed ID: 12616107 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]